Last updated: September 7, 2026
Pertzye is a pancreatic enzyme replacement therapy containing pancrelipase. Its commercial opportunity is tied to chronic exocrine pancreatic insufficiency, especially cystic fibrosis, chronic pancreatitis, pancreatic surgery and other pancreatic disorders. The product has an established FDA approval and differentiated formulation, but it operates in a concentrated market dominated by Creon and Zenpep. Standalone Pertzye revenue is not publicly disclosed, limiting precise valuation and growth analysis.
What is Pertzye and which patients use it?
Pertzye is a delayed-release pancrelipase capsule approved by the FDA for the treatment of exocrine pancreatic insufficiency caused by cystic fibrosis and other conditions. Pancrelipase supplies lipase, protease and amylase enzymes that support the digestion and absorption of dietary fat, protein and carbohydrates.
The product is available in multiple lipase strengths:
| Pertzye strength |
Lipase units per capsule |
| Pertzye 4 |
4,000 |
| Pertzye 8 |
8,000 |
| Pertzye 16 |
16,000 |
| Pertzye 24 |
24,000 |
Pertzye uses enteric-coated, delayed-release microspheres. The formulation is designed to protect enzymes from gastric acid and release them in the duodenum and small intestine. Patients typically take the product with meals and snacks, with dosing adjusted according to body weight, fat intake, symptoms and clinical response. The FDA label imposes maximum daily dosing limits because excessive pancreatic enzyme exposure has been associated with fibrosing colonopathy, particularly in patients with cystic fibrosis. (U.S. Food and Drug Administration [FDA], 2023)
Pertzye is commercially relevant in:
- Cystic fibrosis
- Chronic pancreatitis
- Pancreatectomy
- Pancreatic cancer-related exocrine insufficiency
- Other disorders that impair pancreatic enzyme secretion
When did Pertzye receive FDA approval?
Pertzye received FDA approval in 2012 under New Drug Application 200019. Its approval established the product as one of several FDA-approved pancreatic enzyme replacement therapies in the United States.
| Milestone |
Date or status |
| FDA approval |
2012 |
| Active ingredient |
Pancrelipase |
| Dosage form |
Delayed-release oral capsules |
| Primary regulatory pathway |
New Drug Application |
| Approved use |
Exocrine pancreatic insufficiency |
| FDA regulatory category |
Prescription drug |
| Biosimilar pathway |
Not applicable |
Pertzye is not a biologic in the regulatory sense used for monoclonal antibodies, recombinant proteins or other products regulated under the Public Health Service Act. It is an orally administered enzyme drug regulated as a conventional pharmaceutical product. Biosimilar competition is therefore not the relevant risk. Generic and therapeutically equivalent pancrelipase products are the relevant competitive threat.
Who owns and markets Pertzye?
Pertzye is associated with Digestive Care, Inc. Product materials identify Chiesi USA, Inc. as the commercial distributor or commercial partner for the U.S. product. Public materials do not provide the complete economic terms, royalty structure or minimum-sales obligations of the relationship.
The ownership and commercialization structure matters because Pertzye is not reported as a separately listed product in the public financial statements of a large diversified pharmaceutical company. Digestive Care is privately held, and standalone Pertzye revenue is not routinely disclosed in SEC filings.
This creates a material information limitation for investors and licensing counterparties:
| Financial data point |
Public visibility |
| Annual Pertzye revenue |
Not publicly disclosed as a standalone figure |
| Gross margin |
Not publicly disclosed |
| Prescription volume |
Not consistently disclosed |
| Net price |
Not publicly disclosed |
| Rebate rate |
Not publicly disclosed |
| Product-level EBITDA |
Not publicly disclosed |
| Partner economics |
Not publicly disclosed in full |
What is the financial trajectory for Pertzye?
Pertzye’s financial trajectory is likely characterized by durable demand, moderate market growth and increasing commercial pressure rather than by rapid expansion. The product addresses a chronic condition, and many patients require lifelong enzyme replacement. That supports recurring prescription volume and relatively stable treatment duration.
The principal growth drivers are:
- Longer survival among patients with cystic fibrosis.
- Expanded diagnosis of exocrine pancreatic insufficiency.
- Increased use after pancreatic surgery and in chronic pancreatitis.
- Greater clinical recognition of malabsorption and nutritional complications.
- Periodic supply constraints affecting competing pancrelipase products.
- Price increases or favorable reimbursement positioning.
The principal constraints are:
- Concentration of prescriptions among established brands.
- Prior authorization and formulary restrictions.
- High out-of-pocket costs for chronic therapy.
- Competition from Creon, Zenpep and Pancreaze.
- Potential generic entry into the pancrelipase market.
- Manufacturing complexity involving enzyme sourcing, potency control and enteric coating.
- Limited ability to differentiate products clinically when enzyme replacement is adequately controlled.
Pertzye’s recurring-revenue profile is stronger than that of an acute therapy because discontinuation is generally driven by a change in diagnosis, transplantation, death, intolerance or switching rather than by a short treatment course. Revenue remains exposed to payer discounts and patient affordability because pancreatic enzyme therapy can be expensive over a lifetime.
How large is the pancreatic enzyme replacement market?
The U.S. pancreatic enzyme replacement market is concentrated among a small number of prescription products. Creon is generally regarded as the leading brand, with Zenpep as another major competitor. Pertzye holds a smaller position, while Pancreaze and Viokace address additional segments.
| Product |
Active ingredient |
Typical market position |
Regulatory status |
| Creon |
Pancrelipase |
Leading branded product |
FDA-approved |
| Zenpep |
Pancrelipase |
Major branded competitor |
FDA-approved |
| Pertzye |
Pancrelipase |
Smaller branded competitor |
FDA-approved |
| Pancreaze |
Pancrelipase |
Established alternative |
FDA-approved |
| Viokace |
Pancrelipase |
Non-enteric-coated product used with a proton-pump inhibitor |
FDA-approved |
Market share estimates vary by data source and may differ based on prescriptions, units, sales dollars or patient counts. Public company disclosures generally do not isolate Pertzye market share or revenue.
The market has unusually strong switching friction compared with many conventional oral drugs. Patients and physicians may be reluctant to switch enzyme products because dosing is individualized, symptoms can be difficult to attribute and loss of digestive control can result in weight loss, diarrhea, abdominal pain and nutritional deficiencies. The clinical distinction between products is often less important than dose matching, insurance coverage, availability and patient response.
What formulation protects Pertzye?
Pertzye’s commercial differentiation is based primarily on its delayed-release formulation and enteric-coated microspheres rather than on a new molecular entity.
The formulation is designed to:
- Deliver pancreatic enzymes after passage through the stomach.
- Improve enzyme exposure in the small intestine.
- Permit dosing through multiple capsule strengths.
- Support administration with meals and snacks.
- Provide an alternative for patients who do not tolerate or cannot obtain other pancrelipase brands.
Formulation-related intellectual property can cover the composition of the microspheres, enzyme stabilization, enteric coating, particle size, release characteristics, manufacturing process and combinations of enzyme components. Patent protection for these features is separate from FDA approval and does not necessarily prevent a generic applicant from challenging individual claims.
What patents and exclusivity protect Pertzye?
Pertzye’s initial market protection came from the combination of regulatory exclusivity, formulation patents and the practical difficulty of reproducing a complex enzyme product. The FDA Orange Book is the controlling public source for identifying patents listed for an approved drug product and for determining the listed expiration dates and use codes. (FDA, 2024)
The relevant protection categories are:
| Protection category |
Relevance to Pertzye |
| New chemical entity exclusivity |
Not the principal protection because pancrelipase was previously known |
| New drug approval exclusivity |
Applied at approval under the applicable FDA framework |
| Formulation patents |
May cover delayed release, coating and microsphere composition |
| Manufacturing patents |
May cover enzyme processing, stabilization or coating steps |
| Method-of-use patents |
May cover treatment of exocrine pancreatic insufficiency or dosing applications |
| Trade secrets |
May protect enzyme processing and manufacturing parameters |
| Regulatory supply controls |
Can affect practical competition even after patent expiry |
Pertzye’s patent strength should be assessed claim by claim. Broad claims covering all pancrelipase delayed-release products would face greater validity and design-around pressure than narrow claims directed to a particular coating, particle size or manufacturing step.
Because Pertzye is a conventional pharmaceutical product, it does not receive the type of market exclusivity associated with biologic reference products. The commercial question is whether an abbreviated new drug application can demonstrate pharmaceutical equivalence and bioequivalence, and whether listed patents create a barrier to approval or launch.
When could generic Pertzye competition emerge?
Generic entry depends on the Orange Book patent listing, the timing of any abbreviated new drug application, Paragraph IV certifications, FDA review and litigation outcomes. A generic applicant may certify that a listed patent is invalid, unenforceable or will not be infringed. That certification can trigger patent litigation and, under the Hatch-Waxman framework, may produce a 30-month stay of FDA approval in certain circumstances.
Potential generic entry scenarios include:
| Scenario |
Commercial effect |
| No approved generic |
Continued branded pricing power |
| First Paragraph IV filing |
Litigation risk and possible launch uncertainty |
| First-to-file generic approval |
Potential 180-day exclusivity for the qualifying applicant |
| Authorized generic or licensed launch |
Faster erosion with controlled pricing |
| Multiple generic entrants |
Greater price erosion and payer substitution |
| Formulation-specific challenge |
Limited impact if the generic does not replicate all product characteristics |
Pancrelipase is more difficult to genericize than a simple tablet because the product contains multiple enzyme activities and depends on potency, particle distribution, coating and release characteristics. That complexity may delay entry, but it does not eliminate generic risk.
What is the FDA and Orange Book status of Pertzye?
Pertzye has an active FDA approval as a prescription delayed-release pancrelipase capsule. Its regulatory status should be distinguished from the status of competing products and from the availability of generic pancrelipase products.
The Orange Book is relevant for:
- Listed patents
- Patent expiration dates
- Pediatric exclusivity
- Patent use codes
- Therapeutic equivalence codes
- Approved dosage forms and strengths
The FDA label identifies Pertzye as a pancrelipase product with specified enzyme activities and dosing limitations. Product approval does not guarantee protection from future generic competition because Orange Book listings can expire, be challenged or be bypassed through formulation design-arounds. (FDA, 2023; FDA, 2024)
Which companies challenge Pertzye commercially?
The primary competitive pressure comes from companies selling alternative pancreatic enzyme replacement therapies rather than from direct patent litigants publicly associated with Pertzye.
The competitive set includes:
- AbbVie, associated with Creon
- Nestlé Health Science, associated with Zenpep
- Digestive Care and Chiesi USA, associated with Pertzye
- Other manufacturers and marketers of Pancreaze and Viokace
- Future generic manufacturers entering through the ANDA pathway
Creon has the strongest brand recognition and broad clinical familiarity. Zenpep competes through its established presence in cystic fibrosis and other exocrine pancreatic insufficiency populations. Pertzye’s commercial leverage depends on maintaining supply reliability, securing reimbursement and retaining patients who respond well to its formulation.
What licensing deals affect Pertzye?
The key disclosed commercial relationship is the arrangement under which Chiesi USA markets or distributes Pertzye for Digestive Care. Public sources do not disclose complete transaction economics, including upfront payments, royalties, minimum purchase commitments, field-of-use restrictions or termination rights.
No widely disclosed transaction has established Pertzye as part of a major biologics platform or biosimilar portfolio. Its licensing value is more likely to be assessed through recurring prescription revenue, manufacturing capability, payer access and the remaining life of formulation and manufacturing protections.
What manufacturing barriers protect Pertzye?
Manufacturing is an important practical barrier. Pancrelipase products require control of:
- Enzyme source and biological variability
- Lipase, protease and amylase potency
- Particle size and distribution
- Enteric-coating performance
- Moisture and storage stability
- Batch-to-batch uniformity
- Release testing for multiple enzyme activities
The product’s quality profile can be difficult to reproduce using only the active ingredient description. A generic manufacturer must satisfy pharmaceutical equivalence requirements and demonstrate consistent product performance. Manufacturing failures or shortages can produce immediate revenue loss because patients depend on continuous treatment and physicians may switch permanently to an available competitor.
How does Pertzye compare with Creon and Zenpep?
| Factor |
Pertzye |
Creon |
Zenpep |
| Active ingredient |
Pancrelipase |
Pancrelipase |
Pancrelipase |
| Dosage form |
Delayed-release capsule |
Delayed-release capsule |
Delayed-release capsule |
| Core differentiation |
Microsphere formulation and brand access |
Scale, recognition and broad use |
Established competing formulation |
| Market position |
Smaller branded participant |
Leading branded participant |
Major branded participant |
| Key commercial lever |
Patient retention, access and supply |
Brand scale and formulary presence |
Coverage and clinical familiarity |
| Main risk |
Share loss to larger brands or generics |
Generic erosion and pricing pressure |
Generic erosion and formulary pressure |
Pertzye can remain commercially viable without leading the category because pancreatic enzyme therapy is chronic and patients may remain on a selected product for extended periods. Its ceiling is constrained by the strength of incumbent brands and the absence of a clearly superior clinical outcome demonstrated across the market.
What revenue exposure and launch risks should investors monitor?
Pertzye revenue is most sensitive to prescription retention, net price, reimbursement and supply availability. The absence of public product-level financial reporting means investors should use indirect indicators rather than assume a specific annual sales figure.
Key indicators include:
- FDA shortage listings for pancrelipase products
- Prescription volume by brand
- Payer formulary placement
- Copay assistance and patient-support activity
- New ANDA filings and Paragraph IV litigation
- Orange Book patent expirations
- Manufacturing or recall announcements
- Cystic fibrosis population trends
- Changes in treatment guidelines
- Distribution and licensing changes
A generic launch would not necessarily eliminate Pertzye revenue. Chronic enzyme replacement products often retain a branded segment because of physician familiarity, patient preference, reimbursement differences and supply concerns. The likely outcome is progressive price and volume erosion, with the largest impact occurring after multiple generic entrants.
Key Takeaways
- Pertzye is an FDA-approved delayed-release pancrelipase product for exocrine pancreatic insufficiency.
- Its main commercial markets are cystic fibrosis, chronic pancreatitis and pancreatic surgery-related insufficiency.
- Standalone Pertzye revenue, margins and market share are not publicly disclosed.
- Digestive Care is associated with the product, while Chiesi USA is identified in commercial materials as the U.S. distributor or marketing partner.
- Creon and Zenpep are the principal branded competitors.
- Pertzye’s value rests on chronic recurring demand, formulation know-how, manufacturing capability and patient retention.
- Generic risk is material but technically more complex than for a conventional single-ingredient tablet.
- Biosimilar competition is not applicable because Pertzye is regulated as a conventional pharmaceutical, not a biologic.
- Orange Book patents, Paragraph IV filings and ANDA approvals are the principal legal and regulatory indicators for future erosion.
- The most probable financial trajectory is stable recurring demand with moderate growth potential and increasing pricing pressure as generic and payer competition develops.
Frequently Asked Questions
Is Pertzye a biologic drug?
No. Pertzye is a conventional pancrelipase drug regulated through an FDA New Drug Application. Biosimilar rules do not apply.
Is Pertzye the same as Creon?
Both contain pancrelipase and treat exocrine pancreatic insufficiency, but they are different branded products with distinct formulations, strengths, manufacturing processes and commercial owners.
Can patients switch from Pertzye to a generic pancrelipase product?
A switch may be clinically possible, but dosing must be managed by a healthcare professional because enzyme potency, formulation and patient response can differ.
Does Pertzye have orphan-drug exclusivity?
Pertzye’s principal regulatory protection is not generally analyzed as biologic or orphan-drug exclusivity. Its protection depends on FDA approval, listed patents, formulation know-how and commercial barriers.
What would most increase Pertzye’s value in a licensing transaction?
The strongest value drivers would be durable prescription retention, reliable manufacturing, favorable payer access, defensible formulation claims, limited near-term generic exposure and transparent product-level revenue data.
References
-
U.S. Food and Drug Administration. (2023). Pertzye (pancrelipase) delayed-release capsules: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Cystic Fibrosis Foundation. (2024). Pancreatic enzyme replacement therapy and cystic fibrosis. Cystic Fibrosis Foundation.
-
U.S. Food and Drug Administration. (2012). Pertzye approval history and regulatory information. FDA.
